James Januzzi, MD, and Javed Butler, MD, MPH, MBA, review recent updates in the recommendations for optimal medical care for patients with heart failure with reduced ejection fraction.
EP. 1: Diagnosis of Heart Failure (HF)
Javed Butler, MD, MPH, MBA, discusses the staging and difficulties associated with diagnosing heart failure.
EP. 2: Role of Early Treatment and Gaps in Heart Failure Diagnosis
The role of early aggressive treatment in preventing progression of heart failures and the importance of understanding the root cause of disease.
EP. 3: Heart Failure Treatment in the Healthcare System
A look into the role of heart failure treatment in health care and the overall provision of optimal medical therapy.
EP. 4: ACC Expert Consensus Decision Pathway for HF Treatment
Using the ACC Expert Consensus Decision Pathway documents for the optimization of heart failure treatment and managing the increasing complexity of the disease.
EP. 5: Evolution of Heart Failure Treatments
Experts in cardiology provide a brief history on treatments used for heart failure including ACE (angiotensin converting enzyme) inhibitors and beta blockers.
EP. 6: Using Sacubitril/Valsartan in Heart Failure Treatment
A discussion on the safety and efficacy of angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, for the treatment of heart failure.
EP. 7: Considering ARNIs as De Novo Therapy in Heart Failure
Considerations for initiating sacubitril/valsartan as de novo therapy in patients naïve to angiotensin-converting enzyme inhibitors or angiotensin receptor blocker therapies as per the 2021 update of the expert consensus decision pathway document.
EP. 8: Target Dose in HF Therapies for Reduced Ejection Fraction
Contraindications for clinicians to keep in mind when administering sacubitril/valsartan therapy, and an examination of target dose for therapies in heart failure with reduced ejection fraction.
EP. 9: Role of MRA Blockers in HF Treatment
Evaluating the facilitation of an MRA (mineralocorticoid receptor antagonist) when using an optimal adjuvant medical therapy for the treatment of heart failure.
EP. 10: Evolution of SGLT2 Inhibitors in Treatment Regimens
Javed Butler, MD, MPH, MBA, reviews the historical background of using SGLT2 inhibitors and the impact on patients with heart failure with reduced ejection fraction.
EP. 11: Role of SGLT2 Inhibitor Therapy for HF Treatment
Insights on approaching the initiation of SGLT2 inhibitors for the treatment of heart failure with reduced ejection fraction.
EP. 12: Challenges for Achieving Optimal Therapy in HF
Cardiology experts discuss challenges in achieving the optimal therapy for patients with heart failure and the influence of patient lifestyle and medical factors.
EP. 13: Emerging Agents for Heart Failure Treatment
James Januzzi, MD, and Javed Butler, MD, MPH, MBA, discuss emerging agents, vericiguat and intravenous (IV) iron, in the treatment landscape for heart failure with reduced ejection fraction and advice for community physicians managing patients with heart failure.
2 Clarke Drive Cranbury, NJ 08512